On December 1, 2020, Wang Yaning officially took office as the CEO of Xinkanghe Biological Medicine.

Mr. Wang Yaning, the new CEO of Xinkanghe Biopharmaceutical Company, officially took office on December 1, 2020, becoming the leader of the company's core executive team. Previously, he served as the Senior Vice President of the Drug Research Institute at Qilu Pharmaceutical Group, Chairman and President of the Qilu Pharmaceutical Innovation Research Center in the United States, and was also responsible for global business development (BD) at Qilu Pharmaceutical.

Mr. Wang Yaning graduated from Beijing Medical University with a degree in Clinical Medicine and worked in the Urology Department of Beijing People's Hospital. He later went to the United States to obtain a master's degree in Molecular Pharmacology. Mr. Wang has nearly 30 years of experience in the biopharmaceutical field. Before joining Qilu Pharmaceutical, he worked at internationally renowned biopharmaceutical companies such as Abbott Biopharmaceuticals and Genentech, possessing rich experience in biopharmaceutical development and team management. He is familiar with the full process management of biopharmaceuticals from preclinical research to various clinical development stages and has served as a member of the Biopharmaceutical Quality Association of the Chinese Pharmaceutical Association, a member of the Biopharmaceutical Innovation Alliance, and a member of the Roche and Abbott China Special Task Force. In the field of innovative drug research and development, Mr. Wang, as the Vice President of the Qilu Pharmaceutical Innovation Research Institute and a member of the Innovative Drug Strategic Committee, actively participates in determining the direction of the group's innovative drug product line, the layout of therapeutic areas, and the establishment of product lines, contributing to Qilu's transformation from generic to innovative drugs and the establishment of innovative product lines.

"I am very pleased to join Xinkanghe Biopharmaceutical, which is an innovative biopharmaceutical company rooted in deep foundational research in immunology and precise translation, a vibrant and innovative company based in China and facing the global market," said Mr. Wang Yaning. "In the context of significant reforms in national regulatory policies that encourage drug innovation, China's innovative drug research and development has entered a new era. I hope to elevate the company to a new stage of development through close cooperation with the team, continuously launching innovative products to provide new treatment options for a wide range of patients."

Xinkanghe Biopharmaceutical was founded by the world-renowned immunologist Academician Dong Chen, and has a core R&D team of returnees with over ten years of experience in the field of antibody drugs. The company is committed to the research and development of First in Class antibody drugs in the fields of immuno-oncology and autoimmune diseases, guided by cutting-edge scientific research and precise innovation. The company's vision is to root its R&D innovation in the field of immunology, based in China and facing the global market, providing safe, precise, and effective new generation therapeutic drugs for patients with tumors and inflammatory diseases. Currently, Xinkanghe Biopharmaceutical's first independently developed antibody new drug IL17-AF project is in Phase I clinical trials. Other product pipelines targeting autoimmune diseases and tumor immunotherapy are also being actively promoted, hoping to enter the clinical validation stage soon to address unmet clinical needs and provide more treatment options for thousands of patients.